From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: Xtract, its balance sheet is not real and it must be doing a placing soon?

By Tom Winnifrith | Friday 9 February 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


In today's podcast I discuss, at length, Dispensa (DISP) and the other three worthless companies in that stable with reference to intangible assets. I then move to Colin Bird's Xtract Resources (XTR) which is, I reckon, running on vapours and whose balance sheet is also, almost entirely, intangibles.. Then there is Skinbiotherapeutics (SBTX) and another RNS that stinks, Kefi (KEFI), chat to 'arry as folks plague me and Ben's Creek (BEN) and why it is a zero. 
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

Black-Swan

Video: Poking Bears And Black Swans

 

SBTX

Is Stuart Ashman lying again?

 

Crime-Scene

So farewell then MichaelWalters.com

Time left: 07:45:34